Respiri Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Respiri heeft een totaal eigen vermogen van A$2.6M en een totale schuld van A$1.1M, wat de schuld-eigenvermogensverhouding op 41.7% brengt. De totale activa en totale passiva bedragen respectievelijk A$6.2M en A$3.6M.

Belangrijke informatie

41.7%

Verhouding schuld/eigen vermogen

AU$1.10m

Schuld

Rente dekkingsratio	n/a
Contant	AU$791.36k
Aandelen	AU$2.64m
Totaal verplichtingen	AU$3.55m
Totaal activa	AU$6.19m

Recente financiële gezondheidsupdates

Recent updates

Respiri Limited's (ASX:RSH) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 08

We're Keeping An Eye On Respiri's (ASX:RSH) Cash Burn Rate

Aug 17

Here's Why We're Watching Respiri's (ASX:RSH) Cash Burn Situation

Apr 29

Here's Why We're Watching Respiri's (ASX:RSH) Cash Burn Situation

Jan 03

Here's Why We're Watching Respiri's (ASX:RSH) Cash Burn Situation

Sep 21

We Think Respiri (ASX:RSH) Can Afford To Drive Business Growth

Jun 07

Respiri (ASX:RSH) Is In A Good Position To Deliver On Growth Plans

Feb 22

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( A$4.0M ) RSH } overtreffen de korte termijn passiva ( A$3.4M ).

Langlopende schulden: De kortetermijnactiva RSH ( A$4.0M ) overtreffen de langetermijnschulden ( A$127.9K ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 11.7% ) RSH wordt als voldoende beschouwd.

Schuld verminderen: RSH had 5 jaar geleden een negatief eigen vermogen, maar is nu positief en is dus verbeterd.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: RSH heeft voldoende cash runway voor 1 maanden op basis van de laatst gerapporteerde vrije kasstroom, maar heeft sindsdien extra kapitaal opgehaald.

Voorspelling contante baan: Er wordt voorspeld dat RSH voldoende kasmiddelen zal hebben voor 1 maanden op basis van de vrije kasstroom schattingen, maar heeft sindsdien extra kapitaal opgehaald.

Respiri Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

We're Keeping An Eye On Respiri's (ASX:RSH) Cash Burn Rate

Here's Why We're Watching Respiri's (ASX:RSH) Cash Burn Situation

Here's Why We're Watching Respiri's (ASX:RSH) Cash Burn Situation

Here's Why We're Watching Respiri's (ASX:RSH) Cash Burn Situation

We Think Respiri (ASX:RSH) Can Afford To Drive Business Growth

Respiri (ASX:RSH) Is In A Good Position To Deliver On Growth Plans

Recent updates

Respiri Limited, Annual General Meeting, Nov 20, 2024

Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.007 loss in FY 2023)

Respiri Limited has filed a Follow-on Equity Offering in the amount of AUD 3 million.

New major risk - Shareholder dilution

New major risk - Share price stability

Respiri Limited has filed a Follow-on Equity Offering in the amount of AUD 1.6 million.

Respiri Limited Announces Executive Changes

New major risk - Share price stability

Respiri Limited has completed a Follow-on Equity Offering in the amount of AUD 1.3876 million.

Respiri Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million.

Less than half of directors are independent

Respiri Limited's (ASX:RSH) CEO Will Probably Find It Hard To See A Huge Raise This Year

Respiri Limited, Annual General Meeting, Nov 15, 2023

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.009 loss in FY 2022)

New major risk - Revenue and earnings growth

New minor risk - Financial data availability

New minor risk - Share price stability

Respiri Limited Appoints Brian Leedman as Non-Executive Director

First half 2023 earnings released: AU$0.003 loss per share (vs AU$0.004 loss in 1H 2022)

Respiri Limited Announces Arkansas Heart Hospital Commences Patients on Wheezo RPM

Respiri Limited Announces Minnesota Lung Center Wheezo Rpm Pilot Program Patient Selection Has Been Finalised and Patient Onboarding Has Successfully Commence

No independent directors

Respiri Announces First Patients Enrolled into Wheezo® Remote Patient Monitoring Programs, Further Validating USA Business Model

Respiri Limited, Annual General Meeting, Nov 15, 2022

Full year 2022 earnings released

We're Keeping An Eye On Respiri's (ASX:RSH) Cash Burn Rate

Respiri Limited Announces Executive Changes

Respiri Limited Announces New £2 Million NIHR-Funded UK Paediatric Asthma Clinical Trial with wheezo

Respiri Limited Appoints Brad Snow as A Non-Executive Director

Respiri Limited Appoints Brad Snow as A Non-Executive Director

Here's Why We're Watching Respiri's (ASX:RSH) Cash Burn Situation

Respiri Limited Announces Resignation of Director of Dr. Thomas Duthy

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Here's Why We're Watching Respiri's (ASX:RSH) Cash Burn Situation

Here's Why We're Watching Respiri's (ASX:RSH) Cash Burn Situation

Full year 2021 earnings released: AU$0.016 loss per share (vs AU$0.013 loss in FY 2020)

Respiri Limited Announces Wheezo Registered and Approved for Sale in the UK Market

We Think Respiri (ASX:RSH) Can Afford To Drive Business Growth

Insider recently bought AU$95k worth of stock

Respiri (ASX:RSH) Is In A Good Position To Deliver On Growth Plans

Respiri Limited Announces New Partnership with Pharmacy 4 Less Banner Group

Respiri Limited Holds Media Events to Mark the Launch of Wheezo

Respiri Limited, Annual General Meeting, Dec 16, 2020

Respiri Limited Files Additional Patent Application

Respiri Limited Announces A Partnership with Entech Electronics for the Global Supply of the Ground Breaking Wheezo

Respiri Limited to Report Fiscal Year 2020 Results on Aug 25, 2020

Respiri Limited announced that it expects to receive AUD 0.09 million in funding

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven